IGFBP3 and Chronic colitis: Genetic and pharmacological blockade of the IGFBP3/TMEM219 signaling successfully preserved ISCs and their self-renewal properties in vitro, enabled proliferation and recovery of intestinal crypts, and ameliorated the signs and symptoms of acute and chronic colitis in preclinical models in vivo.